Serina Therapeutics, Inc. (SER) stock
SERNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.41−0.09 (-6.00%)
Close on Nov 12, 2026Market cap $35.81MP/E –Yield –
Serina Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Serina Therapeutics's profit margin for the twelve months ending Dec 31, 2025 was -14755.4%. For fiscal 2025 it was -14755.4%, against -19894.6% the year before. The highest annual figure on record is 167.1% in fiscal 2023.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -14755.4% | +5139.3 |
| FY2024 | Dec 31, 2024 | -19894.6% | −20061.8 |
| FY2023 | Dec 31, 2023 | 167.1% | +30937.7 |
| FY2022 | Dec 31, 2022 | -30770.6% | −24746.3 |
| FY2021 | Dec 31, 2021 | -6024.3% | −3014.6 |
| FY2020 | Dec 31, 2020 | -3009.7% | −2306.3 |
| FY2019 | Dec 31, 2019 | -703.4% | −166.0 |
| FY2018 | Dec 31, 2018 | -537.4% | −68.7 |
| FY2017 | Dec 31, 2017 | -468.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -6324.8% | +293975.2 |
| Q2 FY2025 | Jun 30, 2025 | -4960.0% | −4994.0 |
| Q3 FY2024 | Sep 30, 2024 | 10071.4% | +4030.0 |
| Q2 FY2024 | Jun 30, 2024 | 10203.9% | −1338.9 |
| Q1 FY2024 | Mar 31, 2024 | -300300.0% | −305826.7 |
| Q4 FY2023 | Dec 31, 2023 | 34.0% | +33821.5 |
| Q3 FY2023 | Sep 30, 2023 | 6041.4% | +33096.9 |
| Q2 FY2023 | Jun 30, 2023 | 11542.9% | +33359.5 |
| Q1 FY2023 | Mar 31, 2023 | 5526.7% | +59646.7 |
| Q4 FY2022 | Dec 31, 2022 | -33787.5% | −25794.9 |
| Q3 FY2022 | Sep 30, 2022 | -27055.6% | −18909.7 |
| Q2 FY2022 | Jun 30, 2022 | -21816.7% | −15130.2 |
| Q1 FY2022 | Mar 31, 2022 | -54120.0% | −50391.4 |
| Q4 FY2021 | Dec 31, 2021 | -7992.6% | −6444.5 |
| Q3 FY2021 | Sep 30, 2021 | -8145.8% | −4460.3 |
| Q2 FY2021 | Jun 30, 2021 | -6686.5% | −710.9 |
| Q1 FY2021 | Mar 31, 2021 | -3728.6% | −147.7 |
| Q4 FY2020 | Dec 31, 2020 | -1548.1% | −1054.3 |
| Q3 FY2020 | Sep 30, 2020 | -3685.5% | −2901.8 |
| Q2 FY2020 | Jun 30, 2020 | -5975.6% | −5162.7 |
| Q1 FY2020 | Mar 31, 2020 | -3580.9% | −2773.4 |
| Q4 FY2019 | Dec 31, 2019 | -493.8% | +524.1 |
| Q3 FY2019 | Sep 30, 2019 | -783.7% | −217.6 |
| Q2 FY2019 | Jun 30, 2019 | -812.9% | −396.9 |
| Q1 FY2019 | Mar 31, 2019 | -807.5% | −709.1 |
| Q4 FY2018 | Dec 31, 2018 | -1017.9% | – |
| Q3 FY2018 | Sep 30, 2018 | -566.1% | – |
| Q2 FY2018 | Jun 30, 2018 | -415.9% | – |
| Q1 FY2018 | Mar 31, 2018 | -98.3% | – |
See a number that looks wrong?